Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)
Standard
Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). / Mohseny, Alexander B; Eikema, Dirk-Jan A; Neven, Benedicte; Kröger, Nicolaus; Shaw, Peter J; Damaj, Ghandi; Dalle, Jean-Hugues; Bosman, Paul V; Delehaye, Fanny; Lankester, Arjan C; Smiers, Frans J; Peffault de Latour, Regis.
in: J PEDIAT HEMATOL ONC, Jahrgang 43, Nr. 7, 01.10.2021, S. e1025-e1029.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)
AU - Mohseny, Alexander B
AU - Eikema, Dirk-Jan A
AU - Neven, Benedicte
AU - Kröger, Nicolaus
AU - Shaw, Peter J
AU - Damaj, Ghandi
AU - Dalle, Jean-Hugues
AU - Bosman, Paul V
AU - Delehaye, Fanny
AU - Lankester, Arjan C
AU - Smiers, Frans J
AU - Peffault de Latour, Regis
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Hepatitis-associated aplastic anemia (HAAA) has been reported in 23% to 33% of patients who received orthotopic liver transplantation (LT) for acute liver disease of unknown origin (nonviral hepatitis). In this situation, hematopoietic stem cell transplantation (HSCT) might be a curative option. Here the authors report on 6 patients who received HSCT after LT for nonviral HAAA hepatitis. The outcomes were interpreted in the context of recently reported immune suppressive therapy (IST) outcomes in 8 patients with HAAA and to HSCT outcomes in patients with HAAA who recovered from hepatitis without undergoing LT. All patients transplanted by using HLA-identical sibling donors (3 of 6) were alive and had normal liver function and hematopoiesis without graft versus host disease. Both patients receiving bone marrow from a matched unrelated donor (MUD) experienced extensive graft versus host disease that was fatal for one patient. Thereby, the authors conclude that HSCT can be considered as a first-choice treatment for this category of patients when HLA-identical donors are available. When no HLA-identical donor is available, IST should be applied as HSCT with other donor sources might be reserved for IST nonresponders or poor responders.
AB - Hepatitis-associated aplastic anemia (HAAA) has been reported in 23% to 33% of patients who received orthotopic liver transplantation (LT) for acute liver disease of unknown origin (nonviral hepatitis). In this situation, hematopoietic stem cell transplantation (HSCT) might be a curative option. Here the authors report on 6 patients who received HSCT after LT for nonviral HAAA hepatitis. The outcomes were interpreted in the context of recently reported immune suppressive therapy (IST) outcomes in 8 patients with HAAA and to HSCT outcomes in patients with HAAA who recovered from hepatitis without undergoing LT. All patients transplanted by using HLA-identical sibling donors (3 of 6) were alive and had normal liver function and hematopoiesis without graft versus host disease. Both patients receiving bone marrow from a matched unrelated donor (MUD) experienced extensive graft versus host disease that was fatal for one patient. Thereby, the authors conclude that HSCT can be considered as a first-choice treatment for this category of patients when HLA-identical donors are available. When no HLA-identical donor is available, IST should be applied as HSCT with other donor sources might be reserved for IST nonresponders or poor responders.
KW - Adolescent
KW - Adult
KW - Anemia, Aplastic/etiology
KW - Child
KW - Child, Preschool
KW - Female
KW - Follow-Up Studies
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Hepatitis/complications
KW - Humans
KW - Liver Transplantation/adverse effects
KW - Male
KW - Prognosis
KW - Retrospective Studies
KW - Societies, Medical
U2 - 10.1097/MPH.0000000000001991
DO - 10.1097/MPH.0000000000001991
M3 - SCORING: Review article
C2 - 33273414
VL - 43
SP - e1025-e1029
JO - J PEDIAT HEMATOL ONC
JF - J PEDIAT HEMATOL ONC
SN - 1077-4114
IS - 7
ER -